drugset / Trial / NCT03792542
Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
Phase 2
Unknown
44 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Jiangsu Cancer Institute & Hospital · collabJiangsu Provincial People's Hospital · collabNingbo No.2 Hospital · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe Third People's Hospital of Hangzhou · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR), Platelet-Derived Growth Factor Receptor(PDGFR), and tumor cell proliferation related kinase c-Kit kinase. Anlotinib is an efficient second line therapeutic agent in treatment for metastatic soft tissue sarcoma which has been approved in clinical trials (ALTER-0203). There is a sort of patients who are not candidate for standard first line chemotherapy that is doxorubicin based. The patients either refused or too old and and debilitated to receive the cytotoxic chemotherapy.
Timeline
- Start
- 2019-01
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |